|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM, H. Lundbeck
CPD
|
|
|
+0.00%
in
0 minute
(closed on 06/25/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Caraco Pharma (AMEX:CPD): Poised for a Turnaround
CPD
|
|
|
-42.82%
in
26 days
(closed on 06/25/09)
On 5/28/09, Caraco Pharma (AMEX:CPD) reported its fiscal year 2009 (FY09) results and provided an update on the status of a recently completed FDA inspection of the Company's manufacturing facilities in Detroit, MI. Net sales for CPD declined by 4% for FY09 to a level of $337.2M (versus $350.4M for FY08). The Company cited lower sales of its manufactured products, price erosion for both manufactured + distributed generic drugs, and a voluntary product recall (of heart drug digoxin) during late FY09 for the revenue shortfall. <> Net income decreased to $20.5M during FY09 compa...
|
BioMedReports.com Most Popular Links
CPD
|
|
|
+0.97%
in
51 days
(closed on 05/30/09)
|
Bullish on CPD ...
CPD
|
|
|
-11.44%
in
237 days
Caraco Pharmaceutical Laboratories, Ltd. engages in the development, manufacture, and marketing of generic, prescription, and over-the-counter pharmaceuticals. The company offers Allopurinol, an anti-gout; Amifostine for injection used as oncology adjunct; Amlodipine Besylate tablets, Atenolol, Carvedilol, and Metoprolol Tartrate, which are antihypertensive drug/beta blockers; Baclofen and Tizanidine, which are skeletal muscle relaxants; Carbamazepine, Gabapentin, Phenytoin Sodium extended release capsules, Zonisamide, and Oxcarbazepine, which are anticonvulsants; Carbidopa and Levodopa ER ...
|
Three Oversold Healthcare Catalyst Stocks
CPD
|
|
|
+10.40%
in
28 days
(closed on 04/09/09)
Three Oversold Healthcare Catalyst Stocks With the S&P 500 SPDR ETF (SPY) trading about 8% below its 50-day moving average (DMA), I went in search of oversold healthcare stocks trading at least 16% below their 50 DMA which have potential catalysts within the next six months that may provide some very nice returns. <> The Healthcare Sector SPDR (XLV) is trading about 12% below its 50 DMA amidst concerns of sweeping healthcare reform that would threaten the profits of health insurers, managed care companies, big pharma, and biotechs – although such concerns may be ove<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
From the Blogosphere
Generic Drug Makers
Here’s another terrific post by Pharmboy, this time discussing Generic Drug Makers. - Ilene Generic Drug Makers<script type="text/javascript" src="http://cdn.pis.picapp.com/IamProd/PicAppPIS/JavaScript/PisV4.js"></script> Courtesy of Pharmboy Coming to the end of a good year, and good riddance for some! Whilst the market has been irrational for some time, it is not about what we think but rather about what others that have money think. I have my notions, and here are a few companies that may do well in the New Year with a passed health care reform bill. <>I really like the generic market ri...
|
Mylan: Generic Drugmaker with a Strong Portfolio
<>Mylan Pharmaceuticals (MYL) keeps coming up on my radar so I would like to take the time to analyze the stock and give some recommendations on it. Mylan is approaching its 52 week high so is it a buy or not? In October 2008, they reached a 52 week low of 5.75 and today is trading at 14.88. So that old adage of Buy Low-Sell High is coming into play. In these economic times many rules of trading are finding exceptions to that rule. Mylan's Financial picture can be found on Google Finance here. I see a good exception to Mylan's future, and see the company's stock rising based on FDA approvals ...
|
Caraco Pharmaceutical: Underappreciated and Undervalued, Part 1
Investment Thesis Caraco (CPD) has annual $350M in sales and $32M in net income. The company has almost no CapEx, and over $45 in net cash. The company sells for a market cap of $116M and an EV of $70M, an EV-to-earnings multiple of 2x. The management has publicly stated a 25% sales growth for FY 2009 and should be growing revenue in high double-digits after that. At current prices, you are getting a dollar for 15 cents (we think the company should sell for 12x net income).
|
Caraco Pharma Poised for a Turnaround
On 5/28/09, Caraco Pharma (AMEX:CPD) reported its fiscal year 2009 (FY09) results and provided an update on the status of a recently completed FDA inspection of the Company's manufacturing facilities in Detroit, MI. Net sales for CPD declined by 4% for FY09 to a level of $337.2M (versus $350.4M for FY08). The Company cited lower sales of its manufactured products, price erosion for both manufactured + distributed generic drugs, and a voluntary product recall (of heart drug digoxin) during late FY09 for the revenue shortfall. <> Net income decreased to $20.5M during FY09 compared to $35.4M in th...
|
Three Oversold Healthcare Catalyst Stocks
|
|
|
With the S&P 500 SPDR ETF (SPY) trading about 8% below its 50-day moving average (DMA), I went in search of oversold healthcare stocks trading at least 16% below their 50 DMA which have potential catalysts within the next six months that may provide some very nice returns.
The Healthcare Sector SPDR (XLV) is trading about 12% below its 50 DMA amidst concerns of sweeping healthcare reform that would threaten the profits of health insurers, managed care companies, big pharma, and biotechs – although such concerns may be overblown given the failed attempts at large scale healthcare reform in < />< />< />< />< />< /><>< />< />< />< />< />< />< />< />< />< /><><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< />< />...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Caraco Pharmaceutical Labortories Ltd
- Answers.com
